SCHOLAR ROCK HOLDING CORP (SRRK) Stock Fundamental Analysis
NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD
SRRK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability. SRRK is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SRRK had negative earnings in the past year.
In the past year SRRK has reported a negative cash flow from operations.
SRRK had negative earnings in each of the past 5 years.
SRRK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRRK's Return On Assets of -89.85% is on the low side compared to the rest of the industry. SRRK is outperformed by 73.50% of its industry peers.
The Return On Equity of SRRK (-152.56%) is worse than 64.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.85% | ||
| ROE | -152.56% | ||
| ROIC | N/A |
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRRK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SRRK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRRK has more shares outstanding
The number of shares outstanding for SRRK has been increased compared to 5 years ago.
The debt/assets ratio for SRRK has been reduced compared to a year ago.
2.2 Solvency
SRRK has an Altman-Z score of 13.03. This indicates that SRRK is financially healthy and has little risk of bankruptcy at the moment.
SRRK has a better Altman-Z score (13.03) than 90.81% of its industry peers.
SRRK has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.37, SRRK is doing worse than 72.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.03 |
ROIC/WACCN/A
WACC9.93%
2.3 Liquidity
SRRK has a Current Ratio of 6.04. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
SRRK's Current ratio of 6.04 is fine compared to the rest of the industry. SRRK outperforms 63.78% of its industry peers.
A Quick Ratio of 6.04 indicates that SRRK has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.04, SRRK is doing good in the industry, outperforming 64.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.04 | ||
| Quick Ratio | 6.04 |
3. Growth
3.1 Past
SRRK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.62%.
EPS 1Y (TTM)-23.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 24.41% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.84%
EPS Next 2Y14.46%
EPS Next 3Y26.57%
EPS Next 5Y24.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRRK. In the last year negative earnings were reported.
Also next year SRRK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SRRK's earnings are expected to grow with 26.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.46%
EPS Next 3Y26.57%
5. Dividend
5.1 Amount
SRRK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.76
-0.15 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners117.27%
Inst Owner Change0.01%
Ins Owners1.07%
Ins Owner Change-6.66%
Market Cap3.11B
Analysts85.33
Price Target51.44 (57.02%)
Short Float %18.18%
Short Ratio13.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.1%
Min EPS beat(2)-13.59%
Max EPS beat(2)3.39%
EPS beat(4)2
Avg EPS beat(4)-2.63%
Min EPS beat(4)-13.59%
Max EPS beat(4)3.39%
EPS beat(8)6
Avg EPS beat(8)8.24%
EPS beat(12)8
Avg EPS beat(12)10.38%
EPS beat(16)8
Avg EPS beat(16)3.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 23.26 | ||
| P/tB | 23.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.46
EYN/A
EPS(NY)-2.39
Fwd EYN/A
FCF(TTM)-1.78
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.85% | ||
| ROE | -152.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.85% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.04 | ||
| Quick Ratio | 6.04 | ||
| Altman-Z | 13.03 |
F-Score3
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)14.34%
Cap/Depr(5y)103.43%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22%
EPS Next Y2.84%
EPS Next 2Y14.46%
EPS Next 3Y26.57%
EPS Next 5Y24.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.24%
EBIT Next 3Y34.81%
EBIT Next 5YN/A
FCF growth 1Y-28.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.72%
OCF growth 3YN/A
OCF growth 5YN/A